Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
343
resultados
Última actualización
03/08/2026 [08:30:00]
Resultados 325 a 343 de 343
Resumen de: WO2025037271A1
Provided herein are methods and assays for detecting central nervous system (CNS)-derived tau peptides in blood-based samples from subjects, involving the use of a capture antibody that binds to a tau epitope, and a detection antibody that binds to an epitope comprising amino acids residues that span the junction of Exon 4 and Exon 5 of CNS-derived tau.
Resumen de: WO2025024265A1
The present application relates to methods for quantifying citrullination and methods that may be used to assess the activity of agents including PAD4 (peptidyl arginine deiminase 4) modulators, such as small molecules or antibodies, for example. In certain embodiments, the methods comprise assessing citrullination of one or more citrullination sites on a protein or a peptide fragment thereof present in a biological sample.
Resumen de: US2025154606A1
Provided herein are methods for predicting characteristics, such as activity, function and/or differentiation state of an in vitro population of neuronal cells, for instance a population of neuronal progenitor cells, as well as methods for selecting and/or implanting an in vitro population of neuronal progenitor cells having desired characteristics. Also provided herein are computing devices for performing the provided methods as well as related compositions, articles of manufacture, and kits, including for use in methods of treating a subject having a neurodegenerative disease, for instance Parkinson's disease.
Resumen de: MX2026002775A
The present disclosure relates in some aspects to methods and compositions for detecting an amyloid-related disease in an individual.
Resumen de: KR20260081349A
0001a 본 발명은 타겟 물질에 결합할 수 있는 캡쳐 및 상기 캡쳐 상에 결합된 캡쳐 프로프가 고정된 용기에 타겟 물질을 포함하는 시료를 가하여, 상기 캡쳐에 타겟 물질을 결합시키는 단계; 상기 용기를 세척하여, 시료 중 상기 캡쳐에 결합하지 않은 물질을 제거하는 단계; 상기 용기에 상기 캡쳐 프로브에 결합하는 검출 프로브를 가하여, 상기 검출 프로브 중 적어도 일부를 상기 캡쳐 프로브에 결합시키는 단계; 및 상기 용기내 전극에 상기 캡쳐 프로브에 결합하지 않은 검출 프로브를 결합시켜, 결합 전 후의 전기적 신호 변화를 측정하는 단계;를 포함함으로써, 빠르고 간편한 방법으로 시료내 타겟 물질의 존부를 확인하고, 그 양을 정량화할 수 있도록 하는 타겟 물질의 검출 방법에 관한 것이다.
Resumen de: WO2025081242A1
The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.
Resumen de: WO2026117508A1
The present disclosure provides methods of predicting/diagnosing immunotherapeutic toxicity in a subject using levels of at least one biomarker protein in a biological sample from the subject, wherein the at least one biomarker protein comprises C4orf47, CXCL1, LMNTD2, ERVV-1, PSRC1, SPRED2, KIF22, MRRF, DAAM1, ABO, MAP9, or any combination thereof. Also provided herein are methods of determining therapeutic regimens for patients based on the biomarker levels.
Resumen de: US20260155261A1
Disclosed are non-pharmaceutical compositions, kits, systems, and methods configured to support immunological fitness and continuous cellular defenses. In certain embodiments, a kit includes a bioavailability-optimized ingestible powder and a bioavailability-optimized ingestible liquid provided together with guidance associating coordinated use of the compositions with activation of one or more biological defense pathways. Additional embodiments include preparedness kits comprising interim vitamin D dosing components and guidance materials suitable for deployment prior to individualized testing. System embodiments may integrate distribution mechanisms, data association components, processing components, and optional environmental sensing to support population-scale risk mitigation. Methods are disclosed for supporting immunological fitness, maintaining biological barriers, and associating measurable biological and environmental metrics with population-level risk assessment and actuarial applications, without requiring pharmaceutical intervention.
Resumen de: US20260153437A1
The invention relates to a multispectral plasmonic sensor for chiral molecular barcoding, employing a pixelated array of nanostructured plasmonic units coupled with a photonic cavity. Each pixel is tuned to resonate at distinct mid-infrared (mid-IR) wavelengths, facilitating simultaneous detection of molecular chiral and vibrational properties. The system generates near-perfect resonant absorption, maximizing electric and magnetic field enhancements. When illuminated with circularly polarized light, the sensor produces a chiral near-field with handedness determined by the polarization direction. The interaction between the sensor and chiral molecules is quantified using dissymmetry factors, forming unique chiral barcodes that encode molecular behavior across multiple wavelengths. The sensor enables surface-enhanced infrared absorption (SEIRA) induced surface-enhanced vibrational circular dichroism (SEVCD) measurements, providing comprehensive chiral and vibrational analysis. This approach creates a unique barcode for every chiral active molecule, supporting advanced applications in chemical analysis and molecular identification.
Resumen de: WO2026115269A1
The present invention provides a method for detecting an analyte in a sample, the method comprising steps (i)-(iv). Thus, the present invention provides a method for detecting an analyte in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region having an absence of the optical component. It is the set of local regions of the optical component having an absence of the optical component that are detected.
Resumen de: US20260152551A1
0000 The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
Resumen de: US20260152566A1
0000 Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
Resumen de: AU2024378628A1
It has proven difficult to automate the detection of neurodegenerative disorders in patients. Thus, detection is currently still performed via visual inspection. Accordingly, embodiments automate the detection of neurodegenerative disorders by deriving sleep biomarker(s) from physiological data, acquired while a subject is sleeping, and applying a classifier to the sleep biomarker(s) to output a risk probability for each neurodegenerative disorder. Embodiments also characterize the neurodegenerative disorder(s) by assigning a risk severity based on the risk probability(ies), output by the classifier.
Resumen de: WO2026116669A1
The present invention relates to a novel microRNA for in vitro early diagnosis of mild cognitive impairment and Alzheimer's dementia, and a convergence diagnostic cartridge and diagnostic device using same. The novel miRNA of SEQ ID NO: 1 obtained by molecular analysis exhibits differences in expression levels in the plasma of a normal group, a mild cognitive impairment patient group, and an Alzheimer's dementia patient group, and has the effect of reducing the expression levels of mild cognitive impairment- and Alzheimer's dementia-related proteins. Therefore, by using a novel miRNA present in plasma as a molecular diagnostic index in a non-invasive manner, the present invention enables not only early diagnosis of Alzheimer's dementia but also screening for mild cognitive impairment and Alzheimer's dementia.
Resumen de: US20260151513A1
0000 Compositions and methods for the treatment of leukodystrophy, particularly, H-ABC are disclosed.
Resumen de: US20260151494A1
The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
Resumen de: US20260153520A1
0000 The present invention relates to a method of detecting one or more tissue-derived aggregated proteins in a biological sample.
Nº publicación: JP2026518215A 04/06/2026
Solicitante:
モレキュラーユーコーポレーション
Resumen de: WO2024239122A1
Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
BOPI
Sede Electrónica
